CACindy L. Amundsen

Cindy L. Amundsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cindy L. Amundsen has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Urgency urinary incontinence, one condition, or many? Cluster analysis of physiological variables in the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) II cohort.

    by John O.L. DeLancey, Victor P. Andreev, Calvin Andrews, Farshad Samadifam, Anna Kirby, Cindy L. Amundsen, Payton Schmidt, H.HEnry Lai, Ziya Kirkali, Claire Yang, et al.

  • Open Access

    Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study

    by Cindy L. Amundsen, Suzette E. Sutherland, John P. F. A. Heesakkers, Philip Toozs-Hobson, Frank Martens, Rebecca J. McCrery, Kevin Benson, Kevin J. Cline, Peter R. Rodine, Roger R. Dmochowski

    Revi® is a novel implantable tibial neuromodulation (iTNM) system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (UUI). The Revi System (manufactured by BlueWind Medical) is the first FDA-cleared implantable neuromodulation device that can be used in traditionally non-refractory patients. Three-year follow-up results from the pivotal FDA-approval trial, the OASIS Study, are presented. The Revi System was implanted in 151 women. The primary efficacy and safety endpoints were assessed at 6 and 12 months, respectively; thereafter, participants were consented to extend follow-up to 3 years for assessments of long-term treatment durability and safety. Ninety-three percent (140/151) completed the 12-month study and 85% (119/140) met screening criteria and consented to the 36-month extension study. Ninety participants (76%, (90/119) completed the 36-month assessment and 79% (71/90) were therapy responders (≥ 50% reduction in UUI episodes, demonstrated on a 3-day voiding diary). Sustained therapeutic responses were reported, with durable effectiveness between 6 and 36 months (response rates of 78% and 79%, respectively).Notably, 95% (83/87) reported therapeutic satisfaction and 82% (74/90) reported feeling "much better" or "very much better" based on the Patient Global Impression of Improvement (PGI-I) scale. No device- or procedure- related serious adverse events were reported through 36 months. In women with UUI, Revi - an iTNM system powered by a patient-controlled, external wearable ankle device - showed meaningful and durable efficacy, high patient satisfaction, and an excellent safety profile through 3 years.


  • Open Access

    Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection

    by Daniel P. Marshall, Isha Chugh, Cindy L. Amundsen, Nazema Y. Siddiqui, Warren M. Grill

    Sacral neuromodulation is an effective therapy to control overactive bladder symptoms, yet the underlying mechanisms and optimal stimulation parameters remain unclear. Analysis of 45 clinical studies from 1994 to 2023 demonstrated no significant change in rates of long-term symptom control despite technological advancements, and analysis of recent studies (2015 onward) showed that more than 40% of patients receiving test stimulation do not benefit from sacral neuromodulation. Critical knowledge gaps persist. A lack of evidence guiding stimulation parameter selection has resulted in largely unchanged programming protocols since initial US Food and Drug Administration (FDA) approval in 1997. There is little knowledge of sacral nerve anatomy or nerve fiber organization, and the specific neural pathways mediating therapeutic effects remain unclear. Additionally, there is a limited understanding of how anatomical variations affect stimulation outcomes and few validated predictors of long-term success. We propose that developing detailed computational models incorporating realistic nerve morphology and tissue properties, combined with systematic documentation of programming parameters and outcomes will enable development of more effective stimulation protocols and electrode designs. Bridging these knowledge gaps is essential for improving the consistency and efficacy of sacral neuromodulation for refractory overactive bladder.

  • Open Access

    Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence

    by John P. F. A. Heesakkers, Philip Toozs-Hobson, Suzette E. Sutherland, Alex Digesu, Cindy L. Amundsen, Rebecca J. McCrery, Stefan De Wachter, Emily R. Kean, Frank Martens, Kevin Benson, et al.

    The BlueWind Medical Device, Revi®, is a novel implantable tibial neuromodulation system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (i.e., overactive bladder wet). The Revi System is the first FDA-cleared implantable neuromodulation device which can be used without prior failure with more conservative treatment options. Two-year follow-up results of the OASIS Study are presented. The Revi System was implanted in 151 female participants. The primary efficacy and safety endpoints were assessed at 6- and 12-months, after which participants either consented to extend follow-up for long-term assessment of treatment durability and safety, or they chose to exit the study. Ninety-seven participants completed the 24-month assessment, and of these, 79% were therapy responders (≥ 50% reduction in urgency urinary incontinence episodes (UUIE), demonstrated on a 3-day voiding diary). Importantly, therapeutic response was durable, with comparable effectiveness at 6-, 12-, and 24-months (response rates of 78%, 82%, and 79%, respectively). Participants that completed both the 6- and 24-month assessment had similar demographics and treatment results at the 6-month visit, indicating that these results at 24-months are representative of the overall study population.In addition, high satisfaction and patient impression of improvement were reported, with 97% (88/91) of the participants satisfied with the therapy and 80% (78/97) feeling "much better" or "very much better". There were no serious adverse events related to the device or the procedure through 24 months. Two-year results demonstrate durable efficacy, high patient satisfaction, and a very favorable safety profile.


  • Open Access

    Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-analysis

    by Cindy L. Amundsen, Suzette E. Sutherland, Stephanie J. Kielb, Roger R. Dmochowski

    Introduction Implantable tibial neuromodulation (iTNM) systems have recently become commercially available in the US, and offer a new method of neurostimulation for the treatment of overactive bladder (OAB). In the absence of head-to-head studies, the aim of this meta-analysis was to indirectly compare the efficacy and safety of sacral neuromodulation (SNM) and implantable tibial neuromodulation (iTNM) for the treatment of OAB. Methods A comprehensive search was performed using terms for OAB and neuromodulation. Primary efficacy measures included a ≥ 50% reduction in urgency urinary incontinence (UUI) episodes, urinary frequency, and/or OAB symptoms. Primary safety measures included the rate of device-related adverse events (AEs). Results A total of 20 studies met selection criteria, encompassing 1416 patients treated with SNM and 350 patients treated with iTNM. No comparative or placebo-controlled studies for SNM and iTNM were identified, and therefore the analysis was completed using single-arm results. Weighted averages showed that the UUI responder rate was similar for both SNM and iTNM (71.8% and 71.3%, respectively). Similarly, weighted averages of OAB responder rates were 73.9% for SNM and 79.4% for iTNM. Similar rates of device-related AEs were also observed. Conclusions This meta-analysis found similar efficacy and safety of SNM and iTNM for the treatment of OAB and UUI, including UUI and OAB symptom response rates, reduction in UUI episodes, significant improvements in quality-of-life (QoL), and low rates of procedure and device-related adverse events. Notably, this comparable efficacy was seen without the use of a trial phase of neuromodulation in the iTNM studies versus SNM studies.


  • Open Access

    Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN): An introduction to the Urinary Urgency Phenotyping Protocol LURN II

    by Anne P. Cameron, Claire C. Yang, Catherine S. Bradley, James W. Griffith, Ziya Kirkali, J. Quentin Clemens, Karl J. Kreder, Kimberly S. Kenton, Victor P. Andreev, Cindy L. Amundsen, et al.

    Aims: The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) is undertaking a new cohort study in LURN II including cases and controls.Methods: This new cohort was enrolled to specifically study urinary urgency and urgency urinary incontinence, lower urinary tract symptoms (LUTSs) that are often difficult to treat due to a lack of understanding of their phenotypes and pathophysiologies.Results: This paper will focus on the motivation for the second iteration of LURN and highlight the new research techniques and plans for more thorough phenotyping of this population.Conclusions: This paper will outline the gaps in understanding in treating LUTSs, specifically urinary urgency.


  • Longitudinal changes in symptom‐based female and male LUTS clusters

    by Cindy L. Amundsen, Margaret E. Helmuth, Abigail R. Smith, John O.L. DeLancey, Catherine S. Bradley, Kathryn E. Flynn, Kimberly S. Kenton, H. Henry Lai, David Cella, James W. Griffith, et al.

    Aims: Lower urinary tract symptoms (LUTS) are diverse in type and variable in severity. We examined symptom change within the Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Observational Cohort study identified clusters over time and tested associations with treatments received.Methods: Patient‐reported LUTS and treatment data were collected at multiple time points between baseline and 12 months from the LURN Observational Cohort study. LUTS severity scores were calculated to summarize changes in symptom reporting over time in previously identified LURN clusters. Repeated measures linear regression models tested adjusted associations between cluster membership and severity scores.Results: Four‐hundred seventeen men and 396 women were classified into improved, unchanged, and worsened symptoms between baseline and 12 months (men: 44.1%, 40.5%, and 15.3%; women: 55.8%, 33.1%, 11.1%, respectively). Improvement in LUTS severity scores varied by cluster (estimated adjusted mean change from baseline range: −.04 change in standard deviations of severity scores (ΔSD) to −.67 ΔSD). Prostate surgery was associated with improved severity scores (−.63 ΔSD) in men, while stress incontinence surgery was associated with improved severity scores (−.88 ΔSD) in women.Conclusion: Symptom improvement varied by cluster indicating response to therapy differs amongst subtypes of patients with LUTS. The differential improvement of patients in clusters suggests mechanistic differences between clusters and may aid in selecting more targeted treatments in the future.


  • Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence

    by Nazema Y. Siddiqui, Jonathan B. Wiseman, David Cella, Catherine S. Bradley, H. Henry Lai, Margaret E. Helmuth, Abigail R. Smith, James W. Griffith, Cindy L. Amundsen, Kimberly S. Kenton, et al.

    We examined how mental health measures, sleep and physical function are associated with the presence and type of urinary incontinence and severity in women seeking treatment for lower urinary tract symptoms. This baseline cross-sectional analysis was performed in treatment seeking women with lower urinary tract symptoms. All participants completed the LUTS (Lower Urinary Tract Symptoms) Tool (Pfizer, New York, New York), which was used to classify women based on urinary incontinence symptoms and measure severity. The PROMIS (Patient-Reported Outcomes Measurement Information System) questionnaire for depression, anxiety, sleep disturbance and physical function, the PSS (Perceived Stress Scale) and the IPAQ-SF (International Physical Activity Questionnaire Short Form) were administered. Multivariable regression modeling was done to assess associations with urinary symptom presence, type and severity. We studied 510 women with a mean ± SD age of 56 ± 14 years. Of the women 82% were Caucasian, 47% were obese and 14% reported diabetes. Urinary incontinence was reported by 420 women (82.4%), including stress urinary incontinence in 70, urgency urinary incontinence in 85, mixed urinary incontinence in 240 and other urinary incontinence in 25. On adjusted analyses there was no difference in any mental health, sleep or physical function measure based on the presence vs the absence of urinary incontinence. Among women with urinary incontinence PROMIS anxiety and sleep disturbance scores were higher in those with mixed urinary incontinence than stress urinary incontinence. Increasing urinary incontinence severity was associated with higher PROMIS depression and anxiety scores, and higher PSS scores. However, higher urinary incontinence severity was not associated with a difference in sleep or physical function. Among treatment seeking women with lower urinary tract symptoms, increasing urinary incontinence severity rather than the presence or type of urinary incontinence was associated with increased depression, anxiety and stress.


  • Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial

    by Cindy L. Amundsen, Yuko M. Komesu, Christopher Chermansky, W. Thomas Gregory, Deborah L. Myers, Emily F. Honeycutt, Sandip P. Vasavada, John N. Nguyen, Tracey S. Wilson, Heidi S. Harvie, et al.